A long-time friend of Tom Fogarty, the Fogarty Institute and the medtech industry, David Cassak is one of the industry’s most well-respected experts, immersed in all aspects as managing partner of Innovation in MedTech, LLC, the publisher of the MedTech Strategist, where he is co-editor-in-chief. He is a frequent speaker at industry events,
Often referred to as the “second brain,” the gut is garnering increased attention as mounting evidence shows the key role it plays far beyond digesting food in influencing our moods and general health. G-Tech Medical, a Fogarty Institute company, is playing a critical role in helping to better understand the complexities of our gut and its 500 million neurons.
Tom Krummel is one of those rare individuals who has seen and experienced medical innovation from every front, including stints as an academic, surgeon, writer, mentor and administrator. He continues to impact the medtech field and patient care as chairman of the Fogarty Institute and co-director of Stanford Biodesign.
We have been looking forward to sitting down with the new CEO of long-time Fogarty Institute partner El Camino Hospital, which provides a forum where innovators can work directly with experienced, recognized physicians and conduct clinical trials, as four companies-in-residence currently are doing. Dan Woods joined the hospital in the fall of 2017, bringing an entrepreneurial spirit,
As the first and only device cleared by the FDA to collect cells from the fallopian tubes, the Mako 7 device, originally developed by nVision, a Fogarty Institute graduate, offers a potential platform for earlier detection of ovarian cancer. The company was recently acquired by Boston Scientific, as the device represents an exciting opportunity for the company to expand its focus on women’s health and provides a potential platform to improve care for women worldwide.
Navigating through the Food and Drug Administration’s (FDA) policies, laws, pathways to approval and potential changes to existing regulations can be an intimidating process, especially for new or early-stage medical device startups. However, the organization has done an admirable job at proactively developing educational programs and reaching out to the industry and consumers.
As any successful medtech company knows, developing an innovative device is just the first step in improving patient care. Once that idea has come to fruition, regulatory approval begins, which is why medtech startups need an ally who can help walk them through the process and be their voice with the regulatory bodies who will ultimately grant approval and reimbursement,
“A truly prosperous American economy is one that is diversified, driven by innovation and works for all people. I believe that to achieve this across the country, we must embrace technology and use it as a vehicle to put people to work. I support advanced American manufacturing, as well as a nationwide investment in high-tech apprenticeships and worker training programs.”
At the Fogarty Institute we depend on our board of seasoned professionals to help us continue to grow and adapt to the medtech market. That’s why we were delighted to add another elite name to our esteemed group, with Stacy Enxing Seng joining as our newest member. With nearly 30 years of experience in the medtech industry,
“There is a better way” is a common mantra heard frequently in discussions between Fogarty Institute mentors and its entrepreneurs. It’s what drives us each day to devise and create new technologies that will transform patient care. And while the process is not always easy, there is nothing more rewarding than seeing a successful patient outcome as a result of a device that was created right here,